Gleevec and Shock - a phase IV clinical study of FDA data

Summary:

Shock is reported as a side effect among people who take Gleevec (imatinib mesylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Cyclophosphamide, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Shock when taking Gleevec. It is created by eHealthMe based on reports of 35,000 people who have side effects when taking Gleevec from the FDA, and is updated regularly.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.

What is Shock?

Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin) is found to be associated with 1,354 drugs and 1,748 conditions by eHealthMe. Check the latest studies of Shock.

On Sep, 08, 2025

35,000 people reported to have side effects when taking Gleevec.
Among them, 73 people (0.21%) have Shock.

Among these 73 people:

How long have people been on Gleevec when they have Shock? *

What is the gender of people who have Shock when taking Gleevec? *

female: 35.21 %
male: 64.79 %

What is the age of people who have Shock when taking Gleevec? *

What are other drugs people take besides Gleevec? *

What are other side effects people have besides Shock? *

Fever: 28 people, 38.36%
Hypotension (abnormally low blood pressure): 19 people, 26.03%
Abdominal Pain: 15 people, 20.55%
Nausea (feeling of having an urge to vomit): 15 people, 20.55%
Ascites (accumulation of fluid in the abdominal cavity): 15 people, 20.55%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 15 people, 20.55%
Pleural Effusion (water on the lungs): 14 people, 19.18%
Blood Creatinine Increased: 14 people, 19.18%
Haemoglobin Decreased: 13 people, 17.81%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 12 people, 16.44%

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 12 people, 16.44%
Gastrointestinal Stromal Tumor: 11 people, 15.07%
Fungal Infection: 6 people, 8.22%
Chronic Phase Chronic Myeloid Leukaemia (blood cancer): 4 people, 5.48%
High Blood Pressure: 3 people, 4.11%
Sepsis (a severe blood infection that can lead to organ failure and death): 3 people, 4.11%
Metastases To Liver (cancer spreads to liver): 2 people, 2.74%
Gastric Cancer (stomach cancer): 2 people, 2.74%
Systemic Sclerosis (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 1.37%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 1.37%

* Approximation only. Some reports may have incomplete information.

Do you take Gleevec and have Shock?

- Check whether Shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gleevec:

Gleevec (35,415 reports)

Shock treatments and more:

Shock (28,534 reports)

How severe was Shock and when was it recovered:

Shock in Gleevec

Browse all side effects of Gleevec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Shock:

Shock (1,354 drugs)

Browse all the conditions that are associated with Shock:

Shock (1,748 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Gleevec) and Gleevec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.